In many hemato-oncology and pathology laboratories, IG/TR clonality testing is part of the daily diagnostic work-up for samples with suspected lymphoproliferations or lymphoma. The BIOMED-2/EuroClonality Consortium established standardized PCR protocols for the detection of clonal proliferations in lymphoproliferative disease. These protocols are now used in many laboratories, partly due to their commercial availability. Usage of the EuroClonality kits made the technical performance of these protocols relatively uncomplicated. However, the technical interpretation requires expertise since the reporting of these assays requires knowledge of T-cell receptor (TR) and immunoglobulin (IG) gene rearrangements, multiple rearrangements patterns and cross-lineage rearrangements.
To improve the standardization and reporting of clonality analysis, the EuroClonality Consortium started a series of quality assessment (QA) schemes in 2008. Since 2015, these schemes are also open to external participants.
More information and registration for the EuroClonality EQA scheme
The EuroClonality EQA scheme is organized in collaboration with the Biomedical Quality Assurance Research Unit of the KU Leuven in Belgium under ISO 17043 (PT-215) accreditation.
More information on the EQA scheme, timelines and registration can be found on the website of the Biomedical Quality Assurance Research Unit.